Revealing the Scope of TB Treatment in the Private Sector
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
A Conversation with Mitchell Warren
We spoke with Mitchell Warren, president of the TB Alliance Stakeholders Association (SHA) about what it means for TB Alliance
Unlocking the Combination: Generating Evidence for TB Drug Regimens
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
COVID-19: a message of solidarity on World TB Day 2020
Since 1982, those engaged in the fight against tuberculosis (TB) have observed 24 March as World TB Day, to commemorate
Progress Through Partnership: Stakeholders in New Treatments
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
TB Alliance Names Dr. Daniel Everitt Vice President and Chief Medical Officer
NEW YORK (February 12, 2020)—TB Alliance has appointed Dr. Daniel Everitt to the position of Vice President and Chief Medical
From Drugs to Regimens: Transforming TB Drug Development
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
Jane Griffiths Joins TB Alliance Board of Directors
NEW YORK (February 3, 2020)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has
TB Research Funding Continues to Fall Short
January 30, 2020—The 2019 G-FINDER report indicates that global investment in tuberculosis (TB) research and development (R&D) levels remain far